Stepping Into Tomorrow: Genomics, AI, and the Blood Science Revolution
October 2025
Nora Bennani, MD
Dr. Bennani discusses innovations in hematology, including personalized medicine, artificial intelligence, and next-generation sequencing.
Skip Nav Destination
Editor's Corner
p53 IHC Testing May Be Reliable Surrogate for Early Identification of TP53-Mutated MDS, AML
October 2025
p53 immunohistochemistry (IHC) may be a useful and timely surrogate testing method for early characterization of TP53-mutated myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
Quadruplet Induction Therapy for MM Achieves High Rate of MRD Negativity in MIDAS Trial
October 2025
Patients who were newly diagnosed with multiple myeloma (MM), were transplant eligible, and were treated with an induction regimen of isatuximab, carfilzomib, lenalidomide, and dexamethasone (IsaKRD) in the phase III MIDAS trial achieved the highest rates of pretransplant measurable residual disease (MRD) negativity.
Study Shows Modest Increased Risk of VTE in Patients With CHIP
October 2025
Results of a cohort study on clonal hematopoiesis of indeterminate potential (CHIP) demonstrate that it may modestly increase the risk of venous thromboembolism (VTE), but probably not to a clinically significant degree.
